• Entera Bio appointed Juan Camilo Arjona Ferreira to its board, effective December 1, 2026.
• He will succeed Haya Taitel, who is stepping down from the board.
• Arjona Ferreira is Organon's head of research and development and chief medical officer, with more than 20 years of clinical development experience.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004854), on October 27, 2026, and is solely responsible for the information contained therein.